Novartis's Ilaris looks promising for gout
This article was originally published in Scrip
Executive Summary
Novartis's injectable interleukin-1 blocker Ilaris (canakinumab) significantly reduced the rate of acute flares of gout in patients who are starting therapy with a uric acid lowering therapy compared with the anti-inflammatory colchicine, showed a Phase II study presented at the recent European League Against Rheumatism (EULAR) meeting in Rome.